AT
The startup develops a therapeutic vaccine utilizing a T-cell immunogen designed to elicit a robust immune response against HIV. This approach aims to provide a potential cure for HIV infection, offering patients a pathway to overcome a chronic viral disease.
Updated 2 months ago
Funding
$13.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
C
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a therapeutic vaccine utilizing a T-cell immunogen designed to elicit a robust immune response against HIV. This approach aims to provide a potential cure for HIV infection, offering patients a pathway to overcome a chronic viral disease.